A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function.
about
B cell repertoires in HLA-sensitized kidney transplant candidates undergoing desensitization therapyDifferential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B CellsDe novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease.Human T-follicular helper and T-follicular regulatory cell maintenance is independent of germinal centersLongitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.Decreased Frequency of Circulating Myelin Oligodendrocyte Glycoprotein B Lymphocytes in Patients with Relapsing-Remitting Multiple Sclerosis.Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapyIs rituximab effective in childhood nephrotic syndrome? Yes and no.B-cell regulation and its application to transplantation.Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?Strategies to overcome the ABO barrier in kidney transplantation.Lupus nephritis and B-cell targeting therapy.B cells and their cytokine activities implications in human diseases.Rabbit anti-human thymocyte immunoglobulin for the rescue treatment of chronic antibody-mediated rejection after pediatric kidney transplantation.Use of polyclonal/monoclonal antibody therapies in transplantation.Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.Absence of Intragraft B Cells in Rejection Biopsies After Rituximab Induction Therapy: Consequences for Clinical Outcome.Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion.Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety.T Lymphocyte Activation Markers as Predictors of Responsiveness to Rituximab among Patients with FSGS.B Cell Therapy for Multiple Sclerosis: Entering an Era.Plasma cell survival in the absence of B cell memory.Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases.Respiratory Distress and Nephropathy in a Young Male With Small-Joint Polyarthritis.Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.Complete B Cell Deficiency Reduces Allograft Inflammation and Intragraft Macrophages in a Rat Kidney Transplant Model.B cell depletion at induction--making bad immunological memory fade?Postoperative rebound of antiblood type antibodies and antibody-mediated rejection after ABO-incompatible living-related kidney transplantation.Monitoring B-cell repopulation after depletion therapy in neurologic patients.Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity
P2860
Q28563989-51A5DDD4-ABB1-4803-94B7-BBE0391519ABQ30279164-BC09C221-0287-4E6C-A135-2869F3F2D975Q34112037-EFFEDA01-F288-4F7C-9439-571FA680ED42Q34398374-2C94CC2D-882E-4502-9A28-6539FD725410Q35418255-EB18A1DB-0085-4EE0-B545-DD6E0A38B809Q35674246-0F041E31-1449-4AA5-8B10-C7E839DE4BC7Q37117624-30C9E002-2378-4DF3-A397-6DD113244991Q38118894-99F120CF-8FD4-47FE-A77F-8B901B324168Q38126085-8B9E0FF4-F523-405A-8F35-C3F1AC28A84CQ38154934-B75A7EC0-9FCB-4FCA-8C71-F895A35A7442Q38573785-FED9BA65-CB19-4C7C-9AD2-76BFA8909E81Q38577657-6A52F71F-25EA-4595-B251-273A7112D136Q38643755-6C8168D4-2EB2-48C7-9500-6F0E8145CC0BQ38665740-115BE8D0-2937-4BD3-9F23-5CFA688C782FQ38674466-6D440F86-0CE3-4BA4-8941-CA51BC5705F4Q38769922-BA25A694-ED5C-4A64-A252-6C7D7881ED46Q38838249-F635DF29-AA38-41DC-AEED-60C9C38E729AQ38839087-8460F80F-D361-45C6-9A5C-E48842EC3CECQ39708039-9097D7C8-3C51-4AF4-AA97-0D8792386C8CQ41527816-B828C5D1-9B25-4FDD-8689-327ADD7BC03FQ42083009-C04AFF4B-08AF-4EFC-9F49-1AB05FAB8B46Q46583404-3EEACC77-A2CE-49A7-9698-3DF83AE4E0BCQ47113778-68CA6B3C-2D88-4642-BFF3-B0E1DC9538C6Q47198384-25B0702C-CACD-4171-83E8-0930216A5701Q48106620-C57DAE6C-C18A-4E74-8F34-CB16D891F81DQ49978385-393DF967-54E7-4F22-9488-38604C7E3B2BQ50034507-3DC24982-8CAC-4EA3-B809-50E492F8F576Q50756723-770F602F-2799-4BB8-9BBD-3518B05AF6C8Q53007079-F0D10D52-920E-41EC-8AD3-367842445D0FQ55283551-F802C5A6-C256-4F31-86D3-8FEE986C377FQ56908538-7CF81719-20E3-4563-A551-A426B1365FD7
P2860
A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
A single dose of rituximab doe ...... alters phenotype and function.
@en
A single dose of rituximab doe ...... alters phenotype and function.
@nl
type
label
A single dose of rituximab doe ...... alters phenotype and function.
@en
A single dose of rituximab doe ...... alters phenotype and function.
@nl
prefLabel
A single dose of rituximab doe ...... alters phenotype and function.
@en
A single dose of rituximab doe ...... alters phenotype and function.
@nl
P2093
P2860
P356
P1476
A single dose of rituximab doe ...... alters phenotype and function
@en
P2093
H J P M Koenen
I J ten Berge
K J E Borgman
P2860
P304
P356
10.1111/AJT.12220
P407
P577
2013-04-09T00:00:00Z